Victor Miller - Orgenesis Chief Officer
Executive
Victor Miller is Chief Officer of Orgenesis
| Age | 54 |
| Phone | 480 659 6404 |
| Web | https://orgenesis.com |
Victor Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of Victor Miller against Orgenesis otc stock is an integral part of due diligence when investing in Orgenesis. Victor Miller insider activity provides valuable insight into whether Orgenesis is net buyers or sellers over its current business cycle. Note, Orgenesis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Orgenesis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Victor Miller over six months ago Insider Trading | ||
Victor Miller over six months ago Acquisition by Victor Miller of 25000 shares of Orgenesis at 0.5 subject to Rule 16b-3 | ||
Victor Miller over a year ago Acquisition by Victor Miller of 200000 shares of Orgenesis subject to Rule 16b-3 |
Orgenesis Management Efficiency
The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.Orgenesis currently holds 22.62 M in liabilities with Debt to Equity (D/E) ratio of 0.64, which is about average as compared to similar companies. Orgenesis has a current ratio of 1.54, which is within standard range for the sector. Debt can assist Orgenesis until it has trouble settling it off, either with new capital or with free cash flow. So, Orgenesis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orgenesis sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orgenesis to invest in growth at high rates of return. When we think about Orgenesis' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| John MS | Tango Therapeutics | N/A | |
| Stephen Prior | AN2 Therapeutics | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Xiaohong She | Adagene | 58 | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Charles Davis | Tango Therapeutics | N/A | |
| MS MBA | Rezolute | 51 | |
| Johannes MD | Lixte Biotechnology Holdings | 69 | |
| Heather MS | Tango Therapeutics | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| MaryAlice JD | Acrivon Therapeutics, Common | 51 | |
| Joshua JD | AN2 Therapeutics | 47 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Gopal MBBS | Rezolute | N/A | |
| Graeme Currie | Pasithea Therapeutics Corp | 58 | |
| Julie Carretero | Tango Therapeutics | 53 | |
| Michael Deperro | Rezolute | N/A | |
| Mustapha Parekh | Design Therapeutics | N/A | |
Management Performance
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 |
Orgenesis Leadership Team
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Victor Miller, Chief Officer | ||
| Osher Rheinisch, General Officer | ||
| Neil CPA, S CFO | ||
| Shimon Hassin, Chief Officer | ||
| Efrat Kunik, Chief Officer | ||
| Pierre Lammeretz, Interim Officer | ||
| Evan Fishman, Chief Officer | ||
| Joseph Carpinelli, Chief Octomera | ||
| Dan Slonim, COO Israel | ||
| Vered MSc, CEO Board | ||
| Pr Ferber, Founder Officer | ||
| Vincent Vandamme, VP Strategy |
Orgenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Shares Owned By Insiders | 21.16 % | ||||
| Shares Owned By Institutions | 4.54 % | ||||
| Number Of Shares Shorted | 56.25 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |